In NSCLC, especially adenocarcinoma, personalized therapeutic approaches have led to the development of increasingly efficacious targeted inhibitors for patients with actionable alterations, including in EGFR, ALK, KRAS, BRAF, RET, ROS1, MET, and NTRK [68]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.